The pharmacokinetic principles behind scaling from preclinical results to phase I protocols

Clinical Pharmacokinetics

Volumn 36, Issue 1, 1999, Pages 1-11

  Mahmood, Iftekhar ^a   Balian, John Dikran ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; AMSACRINE; CEFMETAZOLE; CEFOPERAZONE; CEFPIRAMIDE; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DIAZEPAM; ENPROFYLLINE; ERYTHROMYCIN; ETHOSUXIMIDE; LATAMOXEF; METHOTREXATE; OLEANDOMYCIN; PROPRANOLOL; REMOXIPRIDE; THEOPHYLLINE; TOLCAPONE; VALPROIC ACID;

AEROBIC METABOLISM; ALLOMETRY; BODY SURFACE; BODY WEIGHT; BRAIN WEIGHT; CLINICAL PROTOCOL; DATA ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; METHODOLOGY; NONHUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS, PHASE I; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACOKINETICS; SPECIES SPECIFICITY;

EID: 0032955949     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936010-00001     Document Type: Review

References (58)

1. 1. Mordenti J. Man versus beast. J Pharm Sci 1986; 75: 1028-40
2. 2. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1: 435-61
3. 3. Bischoff KB. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep 1975; 59: 777-93
4. 4. Sugita O, Sawada Y, Sugiyama Y, et al. Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbutamide-sulfonamide interaction in rats. J Pharmacokinet Biopharm 1982; 10: 297-316
5. 5. Lin H, Sugiyama Y, Awazu S, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 1982; 10: 649-61
6. 6. King FG, Dedrick RL, Farris FF. Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum (II) (DDP) in several species. J Pharmacokinet Biopharm 1986; 14: 131-55
7. 7. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071-121
8. 8. Boxenbaum H. Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-27
9. 9. McNamara PG. Interspecies scaling in pharmacokinetics. In: Welling PG, Tse FLS, Dighe SV, editors. Pharmaceutical bioequivalence. New York: Mercel Dekker Inc, 1991
10. 10. Sacher G. Relation of lifespan to brain weight and body weight in mammals. In: Wolstenholme GEW, O'Connor M, editors. CIBA Foundation colloquia on aging. London: Churchill, 1959
11. 11. Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 1984; 9: 177-83
12. 12. Mahmood I, Balian JD. Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85: 411-4
13. 13. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica 1996; 26: 887-95
14. 14. Houston B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-79
15. 15. Lave TH, Dupin S, Schmitt C, et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 584-90
16. 16. Chappel WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 1991; 20: 1-116
17. 17. Voisin EM, Ruthsatz M, Collins JM, et al. Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Regulatory Toxicol Pharmacol 1990; 12: 107-16
18. 18. Mahmood I. Interspecies scaling: predicting clearance of anti-cancer drugs in humans. A comparative study of three different approaches using body weight or body surface area. Eur J Drug Metab Pharmacokinet 1997; 21: 275-8
19. 19. McGovern PJ, Williams MG, Stewart JC. Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispos 1988; 16: 18-22
20. 20. Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs and humans. Cancer Res 1990; 50: 2692-7
21. 21. Sangalli L, Bortollotti A, Jiritano L, et al. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats and humans. Drug Metab Dispos 1988; 16: 749-53
22. 22. Dedrick RL, Forrester DD, Cannon JN, et al. Pharmacokinetics of 1-b-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem Pharmacol 1973; 22: 2405-17
23. 23. Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 1976; 199: 67-73
24. 24. Duthu GS. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci 1985; 74: 943-6
25. 25. EL Sayed MA, Loscher W, Frey HH. Pharmacokinetics of ethosuximide in the dog. Arch Int Pharmacodyn 1978; 234: 180-92
26. 26. Loscher W. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J Pharmacol Exp Ther 1978; 204: 255-61
27. 27. Boxenbaum H. Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 1982; 10: 411-26
28. 28. Sawada Y, Hanano M, Sugiyama Y, et al. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 1985; 13: 477-92
29. 29. Chiou WL, Hsu F-H. Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharm Res 1988; 10: 668-72
30. 30. Mahmood I, Balian JD. Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 1996; 59: 579-85
31. 31. Bonati M, Latini R, Tognoni G. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev 184-85; 15: 1355-83
32. 32. Mahmood I. Interspecies scaling: a comparative study of unbound vs total clearance. Does unbound clearance improve the predictive performance of allometric scaling? Eur J Drug Metab Pharmacokinet. In press
33. 33. Sawada Y, Hanano M, Sugiyama Y, et al. Prediction of the disposition of β-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm 1984; 12: 241-61
34. 34. Tsunekawa Y, Hasegawa T, Nadai M, et al. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Pharmacol 1992; 44: 594-9
35. 35. Evans GH, Nies AS, Shand DG. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 1973; 186: 114-22
36. 36. Widman M, Nilsson LB, Bryske B, et al. Disposition of remoxipride in different species: species differences in metabolism. Arzneimittel Forschung 1993; 43: 287-97
37. 37. Movin-Osswald G, Hammarlund-Udenaes M. Remoxipride: pharmacokinetics and effect on plasma prolactin. Br J Clin Pharmacol 1991; 32: 355-60
38. 38. Gascon RA, Calvo B, Hernandez RM, et al. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: Interspecies scaling in pharmacokinetic interaction. Pharm Res 1994; 11: 945-50
39. 39. Harvey PH, Clutton-Brock TH. Life history variation in primates. Evolution 1985; 39: 559-81
40. 40. Calder III WA, editor. Size, function, and life history. Cambridge (MA): Harvard University Press, 1984
41. 41. Bachmann K. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 1989; 9: 331-8
42. 42. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245: R768-74
43. 43. Dedrick RL, Bischoff KB, Zaharko DZ. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54 Pi 1: 95-101
44. 44. Hutchaleelaha A, Chow H, Mayersohn M. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 1997; 49: 178-83
45. 45. Lave T, Saner A, Coassolo P, et al. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 1996; 48: 573-7
46. 46. Mehta SC, Lu DR. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharm Drug Dispos 1995; 16: 735-44
47. 47. Boxenbaum H, Dilea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995; 35: 957-66
48. 48. Mahmood I. Integration of in-vitro data and brain weight in allometric scaling to predict clearance in humans: some suggestions. J Pharm Sci 1998; 87: 527-9
49. 49. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Ther 1997; 283: 46-58
50. 50. Matsui H, Yano K, Okuda T. Pharmacokinetics of cephalosporin SM-162 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob Agents Chemother 1982; 22: 213-7
51. 51. Nakagawa K, Koyama M, Matsui H, et al. Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimrcrob Agents Chemother 1984; 25: 221-5
52. 52. Siefert HM, Maruhn D, Maul W, et al. Pharmacokinetics of ciprofloxacin. Arzheimittel Forschung 1986, 36: 1496-502
53. 53. Abadia AR, Aramayona JJ, Munoz MJ, et al. Disposition of ciprofloxacin following intravenous administration in dogs. J Vet Pharmacol Ther 1994; 17: 384-8
54. 54. Aramayona JJ, Mora J, Fraile LJ, et al. Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. Am J Vet Res 1996; 57: 547-53
55. 55. Drusano GL, Plaisance KI, Forrest A, et al. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986; 30: 440-3
56. 56. Lave T, Dupin S, Schmitt M, et al. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT): use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 1996; 26: 839-51
57. 57. Mahmood I. Interspecies scaling. Predicting volumes, mean residence time and elimination half-life: some suggestions. J Pharm Pharmacol 1998; 50: 493-9
58. 58. Campbell BD. Can allometric interspecies scaling be used to predict human kinetics? Drug Inform J 1994; 28: 235-45